As I See It: Embracing social media—and regulatory ambiguity

Share this article:

Social media for regulated industry is a green field of opportunity. But to maximize the opportunity, we must accommodate the reality of a messier world. Social media, is messy and the regulatory framework (or lack thereof) is equally so. Get used to it. Embracing social media means embracing regulatory ambiguity. 

It's not going to be easy, or risk-free, or inexpensive. Benjamin Franklin said: “Every problem is an opportunity in disguise.” Facebook's recent medical mandate provides pharmaceutical marketers with an excellent opportunity to acknowledge the full capabilities of social media and embrace the three tenets of Pharmaceutical Marketing 3.0: 

1. For the past 20 years, pharma marketing budgets were dedicated to selling products. The next era of pharma marketing will put the company in charge of education. Not third parties, not KOLs—but the company speaking on behalf of itself. Pharma must realize their own network power.

2. The blockbuster era will be replaced by the era of post-patent medicine. Pharma will need a robust portfolio of lower-cost medications to sell and an army of brand loyalists to buy. Communications programs, supported by social media must be one tool because it's where the digitally empowered people are. 

3. Pharma loses over $30 billion a year through non-compliance. Social media can educate and change patient behavior by earning their trust through transparent dialogue. 

As Marshall McLuhan wrote: “At electric speed, all forms are pushed to the limits of their potential.” Ladies and gentlemen, start your engines and fasten your seatbelts.

Peter Pitts is president, Center for Medicine in the Public Interest, and a former associate commissioner, FDA

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications